Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 10000 iu/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80; water for injections; glycine; monobasic sodium phosphate - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the treatment of anaemia and reduction of transfusion in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. eprex is also indicated in adult patients with mild- to-moderate anaemia (haemoglobin > 100 to <= 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to pre-deposit their complete peri-operative blood needs.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 10000 iu/ml - injection, solution - excipient ingredients: glycine; dibasic sodium phosphate dihydrate; sodium chloride; water for injections; monobasic sodium phosphate; polysorbate 80 - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the treatment of anaemia and reduction of transfusion in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. eprex is also indicated in adult patients with mild- to-moderate anaemia (haemoglobin > 100 to <= 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to pre-deposit their complete peri-operative blood needs.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 10000 iu/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; monobasic sodium phosphate; dibasic sodium phosphate dihydrate; glycine; polysorbate 80 - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the treatment of anaemia and reduction of transfusion in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. eprex is also indicated in adult patients with mild- to-moderate anaemia (haemoglobin > 100 to <= 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to pre-deposit their complete peri-operative blood needs.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 4000 iu/ml - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; polysorbate 80; water for injections; glycine; monobasic sodium phosphate; sodium chloride - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the treatment of anaemia and reduction of transfusion in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. eprex is also indicated in adult patients with mild- to-moderate anaemia (haemoglobin > 100 to <= 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to pre-deposit their complete peri-operative blood needs.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 2000 iu/ml - injection, solution - excipient ingredients: glycine; sodium chloride; dibasic sodium phosphate dihydrate; water for injections; polysorbate 80; monobasic sodium phosphate - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the treatment of anaemia and reduction of transfusion in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. eprex is also indicated in adult patients with mild- to-moderate anaemia (haemoglobin > 100 to <= 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to pre-deposit their complete peri-operative blood needs

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: ammonium sulfate; histidine; water for injections; sodium hydroxide; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose; hydrogenated soy phosphatidylcholine; hydrochloric acid - for the treatment of aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm) and extensive mucocutaneous or visceral disease. caelyx may be used for first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 21 september 2001: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - baclofen, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - lioresal intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - baclofen, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - lioresal intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - baclofen, quantity: 500 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - lioresal intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - cytarabine may be used alone or in combination with other chemotherapeutic agents. it is indicated for induction of remission of leukaemia, particularly for acute myeloid leukaemia, in adults and children. cytarabine has been used for remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia and erythroleukaemia; and in the treatment and maintenance therapy of meningeal leukaemia and other meningeal neoplasms.